20.01.2016 07:00:00

Pixium Vision’s 2016 Financial Calendar

Regulatory News:

Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces its 2016 financial calendar*:

  • 29 January, 2016 – Full year 2015 financial results
  • 27 April, 2016 – Sales for the first quarter of 2016
  • 26 May, 2016 – Annual General shareholders’ Meeting
  • 20 July, 2016 – Half year 2016 financial results
  • 27 October, 2016 – Sales for the first nine month of 2016

* This financial calendar is for indicative purposes only. Pixium Vision may change the above dates if deemed necessary.

About Pixium Vision (www.pixium-vision.com, @PixiumVision)

Pixium Vision’s VRS are associated with a surgical intervention as well as a rehabilitation period.

Clinical trials are currently underway with the VRS IRIS® in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. Pixium Vision has filed IRIS’s CE mark dossier at the end of 2015 and expects CE mark approval by mid-2016.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

The company is EN ISO 13485 certified.

Pixium Vision works in close collaboration with world famous academic partners such as the Vision Institute in Paris and the Hansen Experimental Physics Laboratory at Stanford University.

Pixium Vision is listed on Euronext (Compartment C) in Paris.

ISIN: FR0011950641 ; Mnemo: PIX

IRIS® is a trademark of Pixium-Vision SA

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Registration Document filed with the AMF under number R15-069 on September 23, 2015 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).

Nachrichten zu Pixium Vision SAmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Pixium Vision SAmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!